Are you Dr. Madan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 24 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4000 Cambridge St
Kansas City, KS 66160Phone+1 913-588-1227Fax+1 913-588-7073
Summary
- Dr. Rashna Madan, MD is a board certified pathologist in Kansas City, Kansas. She is currently licensed to practice medicine in Kansas and Connecticut. She is affiliated with The University of Kansas Hospital and is an Assistant Professor at University Kansas School of Medicine.
Education & Training
- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 2006 - 2007
- Memorial Sloan Kettering Cancer Center Oncologic PathologyFellowship, Selective Pathology, 2005 - 2006
- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 2001 - 2005
- Kasturba Medical College ManipalClass of 1997
Certifications & Licensure
- KS State Medical License 2007 - 2025
- CT State Medical License 2005 - 2008
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Cytopathology
Publications & Presentations
PubMed
- 618 citationsGenomic and Functional Approaches to Understanding Cancer AneuploidyAlison M. Taylor, Juliann Shih, Gavin Ha, Galen F. Gao, Xiaoyang Zhang
Cancer Cell. 2018-04-09 - 213 citationsGenomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasJoshua D. Campbell, Christina Yau, Reanne Bowlby, Yuexin Liu, Kevin Brennan
Cell Reports. 2018-04-03 - 120 citationsA Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β SuperfamilyAnil Korkut, Sobia Zaidi, Rupa S. Kanchi, Shuyun Rao, Nancy R. Gough
Cell Systems. 2018-10-24
Press Mentions
- Targeted Inhibition of Histone Deacetylase Leads to Suppression of Ewing Sarcoma Tumor Growth Through an Unappreciated EWS-FLI1/HDAC3/HSP90 Signaling AxisApril 25th, 2019